Taiyen Biotech Co (TPE:1737) Total Liabilities : NT$1,714 Mil (As of Dec. 2024)

View and export this data going back to 2003. Start your Free Trial

What is Taiyen Biotech Co Total Liabilities?

Taiyen Biotech Co's Total Liabilities for the quarter that ended in Dec. 2024 was NT$1,714 Mil.

Taiyen Biotech Co's quarterly Total Liabilities declined from Jun. 2024 (NT$1,884.73 Mil) to Sep. 2024 (NT$1,678.75 Mil) but then increased from Sep. 2024 (NT$1,678.75 Mil) to Dec. 2024 (NT$1,713.56 Mil).

Taiyen Biotech Co's annual Total Liabilities increased from Dec. 2022 (NT$1,549.76 Mil) to Dec. 2023 (NT$1,770.90 Mil) but then declined from Dec. 2023 (NT$1,770.90 Mil) to Dec. 2024 (NT$1,713.56 Mil).

Taiyen Biotech Co Total Liabilities Historical Data

The historical data trend for Taiyen Biotech Co's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Taiyen Biotech Co Total Liabilities Chart

Taiyen Biotech Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Liabilities

Get a 7-Day Free Trial

1,433.49

1,954.26

1,549.76

1,770.90

1,713.56

Taiyen Biotech Co Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Liabilities	Get a 7-Day Free Trial															1,770.90	1,651.34	1,884.73	1,678.75	1,713.56

Taiyen Biotech Co Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Taiyen Biotech Co's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1165.15	+	(31.488	+	479.237
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	37.681	+	0)
	=	1,714

Total Liabilities	=	Total Assets (A: Dec. 2024 )	-	Total Equity (A: Dec. 2024 )
	=	8381.173	-	6667.617
	=	1,714

Taiyen Biotech Co's Total Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1165.15	+	(31.488	+	479.237
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	37.681	+	0)
	=	1,714

Total Liabilities	=	Total Assets (Q: Dec. 2024 )	-	Total Equity (Q: Dec. 2024 )
	=	8381.173	-	6667.617
	=	1,714

Taiyen Biotech Co Total Liabilities Related Terms

Thank you for viewing the detailed overview of Taiyen Biotech Co's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Taiyen Biotech Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Taiyen Biotech Co Ltd (TPE:1737) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 297, Section 1, Chien-Kang Road, South District, Tainan, TWN

Website

https://www.tybio.com

Taiyen Biotech Co Ltd operates in personal care and home care products. Its product portfolio comprises beauty care products, health food, skin products, salt products and spices, bottled water, and medical supplies, among others. The group has four reportable segments; Salt products and packaged water department, Biotech cleaning and maintenance department, Construction and services department, and Other departments.. The Salt and Packaged Product Segment accounts for the bulk of revenue. Geographically it operates through the region of Taiwan; however, it also holds a presence in the international market.

Taiyen Biotech Co Headlines

No Headlines